Vyvanse, Ritalin, Concerta : médicaments TDAH au Québec

Vyvanse, Ritalin, Concerta: which ADHD medication is right for Quebec?

You've just been diagnosed with ADHD - for you or your child. Or your doctor is discussing a treatment adjustment. Or you're trying to understand why the prescribed medication costs more than you expected, why RAMQ covers it only under certain conditions, or what really distinguishes Vyvanse from Concerta.

Medications for ADHD are among the most frequently prescribed in Quebec. They are also among the most misunderstood - by patients, by families, and sometimes by the professionals themselves when they run out of time to explain. This guide introduces you to the medications available in Quebec in 2026, their real differences, their coverage by RAMQ, their side effects, and how choosing the right medication is done in practice.

The two main families of ADHD medications

All medications used for ADHD fall into one of two broad categories: the stimulants and non-stimulants. This distinction is fundamental because it determines the mechanism of action, expected efficacy, possible side effects and prescription rules.

Stimulants are the first-line drugs - they have been used since the 1950s for ADHD and are one of the best-documented drug classes in psychiatry. They act by increasing the availability of dopamine and noradrenaline in the brain's prefrontal circuits, thereby improving sustained attention, impulse control and executive functions. Their efficacy is rapid - often noticeable within the first few days - and affects around 70 to 80 % of patients who try them.

Non-stimulants are used when stimulants are contraindicated, poorly tolerated or insufficiently effective. Their mechanism is different - they act primarily on noradrenergic receptors - and their efficacy, although real, is generally inferior to that of stimulants for the majority of patients.

Stimulants: methylphenidate vs amphetamines

Within stimulants, there are two distinct molecules - the methylphenidate and amphetamines - with different drugs in each family.

Methylphenidate acts primarily by blocking the reuptake of dopamine and noradrenaline at the synapse. It is the oldest and most widely prescribed molecule for ADHD worldwide.

Amphetamines act by both blocking the reuptake and stimulating the release of dopamine and noradrenaline - a slightly different mechanism which explains why some patients respond better to amphetamines than to methylphenidate, and vice versa. It's not a question of ADHD severity - it's a question of individual neurobiological profile that we can't predict in advance without trying.

In clinical practice, if a patient doesn't respond well to one molecule, trying the other is a standard step in optimizing treatment.

Drugs available in Quebec - detailed comparison

Short-acting methylphenidate

Ritalin - the original immediate-release formulation. Duration of action: 3 to 5 hours. Ritalin generally needs to be taken several times a day - morning, noon and sometimes early afternoon. It offers interesting flexibility: doses can be fine-tuned to the patient's needs, depending on the time of day. Ritalin's effects take hold quickly after dosing and dissipate relatively quickly, making it a useful option for patients who need a targeted effect over a specific period or who wish to avoid evening effects.

Generic Ritalin is available in Quebec and covered by RAMQ. It is the least expensive option in the methylphenidate family.

Long-acting methylphenidate

Concerta - sustained-release methylphenidate via OROS technology (osmotic system). Duration of action: 10 to 12 hours. Concerta releases a small amount immediately on intake, then gradually releases the remainder over the course of the day via an osmotic pump built into the capsule. This technology produces a relatively constant action profile, covering the whole school or work day with a single morning dose. Important: the capsule must not be cut or chewed - this would destroy the controlled-release mechanism.

Concerta is covered by the RAMQ. Generic versions are available, but their release profile is not strictly identical to the original brand - some patients notice a clinical difference. If you or your physician observe a difference with the generic, this discussion should be raised during a follow-up consultation.

Biphentin - double-release methylphenidate. Duration of action: 10 to 12 hours. Biphentin releases 40 % of the dose immediately and 60 % gradually - producing a different plasma curve profile to Concerta, sometimes preferred by some patients. Biphentin is a capsule that can be opened and sprinkled on soft food for children who have difficulty swallowing capsules - something Concerta does not allow. Covered by RAMQ.

Foquest - new-generation sustained-release methylphenidate. Duration of action: up to 16 hours, the longest coverage in the methylphenidate family. Foquest has been developed to provide evening coverage for adults whose work and family activities extend well beyond the standard working day. It is covered by the RAMQ under certain conditions - check your current coverage with your pharmacist or physician, as criteria may change.

Amphetamines

Adderall XR - mixture of sustained-release amphetamine salts. Duration of action: 8 to 10 hours. Adderall XR releases 50 % immediately and 50 % progressively four hours later. It is generally well tolerated and effective, with a side-effect profile similar to other stimulants. Covered by RAMQ under certain conditions. The capsule can be opened and sprinkled on soft food.

Vyvanse - lisdexamfetamine, a prodrug. This is where the difference with other stimulants is most significant and least well understood.

The Vyvanse - why it's different

Vyvanse (lisdexamfetamine) deserves a separate section because its mechanism is fundamentally different from all other stimulants.

Vyvanse is a prodrug - the ingested molecule is not active in itself. It must be metabolized in the body, mainly by red blood cells, to release active dexamfetamine. This conversion process is slow, gradual and saturable - meaning that even if you ingest a higher dose, the amount of dexamfetamine released cannot exceed a certain ceiling. Release kinetics are not dependent on capsule technology, but on a metabolic process.

The clinical implications of this mechanism are significant. Vyvanse has a very gradual onset of action - with no abrupt peak or abrupt drop-off, consistent with a clinical experience often described by patients as «milder» and more consistent than other stimulants. It is also associated with a lower abuse potential than other amphetamines - metabolic saturation limits the euphoric effect at high doses.

Vyvanse's duration of action is 12 to 14 hours - the longest of any stimulant available in Quebec.

RAMQ coverage for Vyvanse :

Vyvanse is listed on the RAMQ formulary, but only under certain conditions. exception criteriaspecific. In practice, to be covered by the RAMQ, Vyvanse generally requires prior authorization demonstrating that the patient has tried and failed to tolerate - or responded adequately to - at least one other stimulant. These criteria are subject to change - your doctor will take the necessary steps to ensure that Vyvanse is the right drug for you.

Without RAMQ coverage, the monthly cost of Vyvanse can be significant - several dozen to several hundred dollars depending on the dose, according to available price data. Some private insurers cover it without restriction. If cost is an obstacle, discuss it openly with your doctor - there are often effective therapeutic alternatives with better coverage.

Non-stimulants - when and why

Atomoxetine (Strattera)

Atomoxetine is a selective noradrenaline reuptake inhibitor. Unlike stimulants, it is not a controlled substance - which simplifies prescribing rules. Its efficacy is inferior to that of stimulants for the majority of patients, but it is a valid option for specific profiles: comorbid severe anxiety for which stimulants aggravate symptoms, history of significant tics, cardiac contraindications to stimulants, or high risk of misuse.

Atomoxetine has a delayed effect - clinical benefits generally take 4 to 8 weeks This is very different from stimulants, where the effect is visible within the first few days. This delay is often a source of confusion and premature discontinuation of treatment. Covered by RAMQ.

Guanfacine (Intuniv)

Guanfacine is an alpha-2A adrenergic receptor agonist, originally developed as an antihypertensive. It acts on prefrontal circuits, enhancing noradrenergic modulation. It is particularly useful for symptoms of hyperactivity and impulsivity, tics associated with ADHD, and can be used in combination with a stimulant for a complementary effect. Its efficacy as a monotherapy for ADHD is generally inferior to that of stimulants. Covered by RAMQ under certain conditions.

Bupropion (Wellbutrin) - off-label use

Bupropion is an antidepressant that inhibits the reuptake of dopamine and norepinephrine. It is sometimes used off-label for ADHD, particularly in adults with comorbid depression or in whom stimulants are contraindicated. Its efficacy in ADHD is documented, but inferior to that of stimulants. It is not a first-line treatment.

RAMQ coverage - what's covered, what's not

RAMQ coverage of ADHD medications follows specific rules that change regularly. Here's the general situation in 2026 - always check your current coverage with your pharmacist or physician, as the criteria may have changed.

Generally covered without any particular restrictions: Ritalin and its generics (short-acting methylphenidate), Concerta and its generics (long-acting methylphenidate), Biphentin, Adderall XR under certain conditions, Strattera (atomoxetine).

Covered under exceptional criteria : Vyvanse - generally requires prior authorization documenting failure or intolerance to other stimulants. Foquest - check current criteria. Exception criteria are managed by your physician, who submits a request for authorization to RAMQ - you don't have to do this yourself.

Important information on generics : for sustained-release drugs, switching to a generic may alter the release profile. If you notice a clinical difference after switching to a generic - efficacy, duration of action, side effects - report it to your doctor and pharmacist. In some cases, a «non-substitutable» note may be added to the prescription.

Prescribing rules for controlled substances in Quebec

All the stimulants used for ADHD - methylphenidate and amphetamines - are controlled substances under the Controlled Drugs and Substances Act (Canada). This designation entails specific prescribing rules that patients should be aware of to avoid misunderstandings.

Mandatory manual prescription : stimulant medications cannot be prescribed by telephone, fax or standard electronic means in all situations - a manual prescription signed by the doctor is required. In certain telemedicine contexts, specific rules apply - your doctor will explain how this works in practice for your follow-up at Clinique Omicron.

Limited duration per prescription : Prescriptions for controlled substances have a maximum duration - usually 30 days of treatment per prescription, depending on the drug and provincial rules. This means you'll need to renew your prescription every month - which requires regular contact with your doctor.

Non-renewable by phone : controlled substances cannot be renewed simply by calling or texting the pharmacy - a new prescription is required for each renewal.

These rules may seem restrictive, but they are designed to ensure regular medical follow-up - which is clinically appropriate for drugs that need to be adjusted according to the patient's response.

How Clinique Omicron manages these constraints:

For patients treated at Clinique Omicron, we work to make this process as smooth as possible. Regular follow-up consultations - in person or by teleconsultation, depending on the applicable rules - help maintain continuity of treatment. Your attending physician will explain how renewals work in practice, depending on your situation, at your first consultation.

How the right drug is chosen - the process in practice

There is no blood test, brain scan or biological marker that predicts which drug will work best for a given patient. The choice of treatment is based on clinical assessment and a structured trial-and-fit process.

Factors the doctor considers :

Patient age - some drugs have stronger data in children, others in adults. ADHD presentation - predominantly inattentive, hyperactive-impulsive, combined - may favour certain formulations. Comorbidities - severe anxiety, tics, depression, sleep disorders - may contraindicate certain medications or favor others. Lifestyle and needs - length of coverage required, work or school schedules, evening activities - point to short- or long-acting formulations. Medication response history - if the patient has already taken a stimulant and responded well, this can be a good starting point. Insurance coverage and cost considerations - particularly relevant for Vyvanse.

The adjustment process :

When the first drug is prescribed, it is usually started at the minimum effective dose and adjusted progressively according to response and tolerance. Follow-up at two to four weeks after the start of treatment is standard to assess efficacy, adjust the dose if necessary, and manage any side effects.

If the first drug doesn't work after a proper trial - right dose, right duration - switching to the other molecule (methylphenidate to amphetamines or vice versa) is a standard step, not a failure. Most patients find effective treatment after one or two trials.

Side effects - what's common, what's rare, what to seek advice about

Frequent and generally manageable side effects:

Decreased appetite is the most common side effect of stimulants - often more marked in the middle of the day, when the drug is at its peak action. Most patients adapt to this. Practical strategies help: a hearty breakfast before taking the drug, an evening meal after the effect has worn off, and nutritious evening snacks for children.

Difficulty falling asleep can occur if the medication is taken too late in the day, or if the duration of action is too long for the patient's lifestyle. Adjusting the time of day or switching to a shorter-acting formulation often solves this problem.

Headaches and abdominal pain are common at the start of treatment, and tend to disappear after a few days. Taking with food may help.

Effects on growth in children :

A slight slowdown in growth rate has been documented in some children taking stimulants - of the order of 1 to 2 cm over several years of treatment. This effect tends to normalize over time and is considered clinically acceptable, given the benefits of treatment. Weight and height monitoring are part of standard medical care.

This calls for rapid consultation:

Chest pain, palpitations or irregular heartbeat - report immediately. Stimulants slightly increase heart rate and blood pressure - this effect is generally benign in patients with no cardiovascular history, but requires monitoring in patients with risk factors. Unusual thoughts, behaviours significantly different from normal, or signs of psychosis - rare but should be reported immediately. Appearance or significant worsening of tics.

What Clinique Omicron offers for ADHD medication monitoring

At Clinique Omicron, ADHD medication monitoring is structured to ensure real continuity, not just prescription refills.

At each follow-up visit, your doctor assesses the current efficacy of the treatment - does the medication cover the day well? Are there any rebound periods? Are side effects manageable? Does the treatment need to be adjusted? These questions are part of a rigorous clinical follow-up that goes beyond simply renewing the prescription.

For patients across the province, these follow-up consultations can be done via teleconsultation - convenient, no travel required, with availability posted in real time on cliniqueomicron.ca. Prescription renewals for controlled substances follow the applicable rules, which your doctor will clearly explain to you at your first consultation.

If your current treatment is not optimal - insufficient efficacy, difficult side effects, inadequate coverage for your needs - a treatment review consultation allows you to explore the alternatives available and find the combination that works best for you.

Make an appointment on cliniqueomicron.ca specifying whether this is an existing ADHD follow-up or an initial assessment.

Frequently asked questions

What's the real difference between Vyvanse and Concerta?

These are two drugs from different molecular families. Concerta is long-acting methylphenidate - it acts primarily by blocking the reuptake of dopamine and noradrenaline. Vyvanse is lisdexamfetamine - an amphetamine prodrug with a very progressive action profile and longer duration (12-14h vs. 10-12h). In practice, some patients respond better to one or the other - there is no universal rule. RAMQ coverage is also different: Concerta is generally covered without restriction, while Vyvanse requires exception criteria.

Can my child take medication leave on weekends and during the summer?

Yes, it's a common practice called «medication vacations» - and it's often recommended by doctors, especially for children whose ADHD has a predominantly academic impact. Discontinuing medication during periods without school demands allows appetite to recover, growth to normalize over treatment-free periods, and to check whether treatment is still necessary. This decision should be discussed with your doctor - it is not appropriate for all profiles, especially when ADHD has a significant impact on social relationships or family life outside school.

Can ADHD symptoms be mistaken for autism or PDD?

For some adults with ADHD and variable lifestyles, use according to need is sometimes envisaged - taking the medication on work-intensive days and omitting it on unstressed weekends, for example. This approach is clinically debatable and depends on the individual profile. For children, on-demand use is generally less recommended - regular treatment facilitates dose adjustment and follow-up. Discuss your lifestyle profile with your doctor to determine the most suitable approach.

Is ADHD medication addictive?

It's one of the most common concerns - and scientific data provide a nuanced answer. Stimulants used in therapeutic doses for ADHD are generally not addictive in the clinical sense in patients who really need them. The neurobiological mechanism of ADHD - dopaminergic deficiency in prefrontal circuits - is fundamentally different from that of substance abuse. Epidemiological data show that appropriate medication treatment of ADHD is associated with a reduced risk of substance use disorders in adolescence and adulthood. That said, stimulants have real abuse potential when used by people who don't have ADHD - which is why prescribing rules framing controlled substances exist.

Can I travel in Canada and abroad with my ADHD medication?

In Canada, your prescription drugs can be carried with your original prescription or pharmacy label. For international travel, controlled substances - including ADHD stimulants - are subject to the customs regulations of the destination country. Some countries have strict restrictions or even a total ban on amphetamines. Before any international trip, check the rules of the destination country and, if necessary, obtain a medical letter from your doctor detailing your treatment. Clinique Omicron can produce this type of letter as part of your follow-up care.

 

Medical consultation | Clinique Omicron